In patients with platinum-sensitive, recurrent ovarian cancer who are gBRCA1/2 wild-type, the combination of PARPis with ivonescimab (AK112), bsAbs targeting both PD-1 and VEGF, has been investigated. Here, PDCD1 is linked to ovarian carcinoma.